Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + ipilimumab N01 plus chemotherapy in first-line PD-L1–negative advanced NSCLC
ChiCTR2600119741Phase 2Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of sintilimab and ipilimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Chinese PLA General Hospital. Primary endpoint: Progression-free survival. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
sintilimabipilimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2600119741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119741.